Back to top
more

Pediatrix Medical Group, Inc. (MD)

(Real Time Quote from BATS)

$6.90 USD

6.90
277,618

-0.01 (-0.15%)

Updated Jun 11, 2024 01:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Mednax (MD) Down 12.3% Since Last Earnings Report?

by Zacks Equity Research

Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MEDNAX (MD) Q1 Earnings Miss Estimates, Decline Y/Y

by Zacks Equity Research

MEDNAX's (MD) first-quarter earnings disappoint with weak revenues and elevated expenses.

Mednax (MD) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Mednax (MD) delivered earnings and revenue surprises of -8.45% and -5.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Mednax (MD) Q1 Earnings Expected to Decline

by Zacks Equity Research

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEDNAX Ties Up With Georgia Neonatology for Better Baby Care

by Zacks Equity Research

MEDNAX (MD) forms a partnership with Georgia Neonatology, LLC to improve its pediatric services.

Why Is Mednax (MD) Down 17.6% Since Last Earnings Report?

by Zacks Equity Research

Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y

by Zacks Equity Research

Mednax's (MD) Q4 gains on revenue growth. However, the same is partly offset by rise in expenses.

Mednax (MD) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Mednax (MD) delivered earnings and revenue surprises of 1.10% and 2.81%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

What Lies Ahead for Centene (CNC) Stock in Q4 Earnings?

by Zacks Equity Research

Centene's (CNC) fourth-quarter earnings are likely to gain traction from growth in revenues and membership strength, partly offset by high operating costs.

Mednax (MD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Mednax (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Anthem (ANTM) This Earnings Season?

by Zacks Equity Research

Anthem (ANTM) is likely to gain from Q4 results on revenue and membership growth, partly offset by higher expenses.

Is a Beat in Store for HCA Healthcare (HCA) Q4 Earnings?

by Zacks Equity Research

HCA Healthcare (HCA) is likely to gain from higher admissions in Q4 earnings.

Why You Should Hold Mednax (MD) Stock in Your Portfolio

by Zacks Equity Research

Banking on top-line growth and strategic efforts, Mednax (MD) holds great potential to be a rewarding pick for investors.

Which Stock to Emulate HCA Healthcare (HCA) Success in 2019?

by Zacks Equity Research

While HCA Healthcare (HCA) has been a runaway winner this year, other companies by virtue of strong operating fundamentals are poised for growth in 2019.

Mednax (MD) Up 4.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MEDNAX and Unit Unveil Incubator for Better Patient Results

by Zacks Equity Research

MEDNAX (MD) and its radiology arm launch MDR-AI Incubator to develop products for better patient care.

MEDNAX (MD) Q3 Earnings Fall Short of Estimates, Rise Y/Y

by Zacks Equity Research

MEDNAX's (MD) Q3 earnings grow on the back of the company's operational efficiency as well as its various growth initiatives.

Mednax (MD) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Mednax (MD) delivered earnings and revenue surprises of -2.08% and -0.75%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Q3 Earnings Preview: What to Look Out For

by Zacks Equity Research

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEDNAX Buys Radiology Specialists to Expand Business

by Zacks Equity Research

MEDNAX (MD) boosts its radiology business with the acquisition of Radiology Specialists.

    Should Value Investors Consider MEDNAX (MD) Stock Now?

    by Zacks Equity Research

    Let's see if MEDNAX, Inc. (MD) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

      MEDNAX (MD) Unveils Unit for Better Pediatric Hearing Care

      by Zacks Equity Research

      MEDNAX (MD) opens the doors of MEDNAX Audiology Institute to offer better hearing loss treatment for infants.

        MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE

        by Zacks Equity Research

        On a positive note, the broader healthcare looks delighted with the massive tax cuts. Also, the scenario within the Medical Device space seems equally bright.

          Ensign Group Boosts Arizona Base With Real Estate Buyout

          by Zacks Equity Research

          Ensign Group's (ENSG) inclination toward inorganic growth leads to numerous acquisitions, significantly favoring the company's top line.

            Should Value Investors Pick MEDNAX (MD) Stock?

            by Zacks Equity Research

            MEDNAX (MD) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.